LifeStance (LFST) Q2 2026 Earnings Call Transcript
LifeStance (LFST) reported Q2 2026 results on an earnings call. Revenue rose to $435 million (+26%) on 2.6 million visits (+19%) and total revenue per visit of $167 (+6%). Adjusted EBITDA was $66 million (+94%) with a 15.2% margin. Full-year 2026 revenue guidance was raised to $1.685-$1.725 billion and adjusted EBITDA to $215-$235 million.
How this was made
The 30-second read
Why it matters
The key tradable items are the raised FY 2026 revenue guidance, updated FY adjusted EBITDA range, and the new Q3 revenue and adjusted EBITDA ranges, all supported by higher visit volumes and improved center margins. Offsetting risks include a planned 2027 EHR transition that management expects to cause a short-term productivity blip, and near-term cash flow headwinds from payroll-related outflows.
Market read
Guidance raise plus strong margin expansion typically drives re-rating for profitable growth healthcare services, while the EHR transition risk and cash flow timing can create volatility around near-term estimates.
What to watch
Third-quarter free cash flow is impacted by roughly $60M of payroll and 401(k) outflows, which could matter for investors focused on cash conversion rather than earnings.
Background
LifeStance’s Q2 2026 earnings call covers operating KPIs (visits, clinician base, revenue per visit), profitability (adjusted EBITDA and margin), and forward guidance for FY 2026 and Q3 2026, plus a planned 2027 EHR vendor transition.
Ticker impact
LifeStance reported Q2 2026 revenue of $435M (+26%) and raised full-year 2026 revenue guidance to $1.685B-$1.725B.
Likely near-term positive bias as guidance raise and margin expansion can support multiple expansion, though EHR transition and marketing/tech spend may cap upside.
The article discloses multiple forward-looking datapoints (FY guidance raise, Q3 revenue and EBITDA ranges, and 2027 EHR transition productivity blip risk) that directly affect expectations for LFST’s growth and profitability trajectory.
Market effects
Behavioral health providers may see read-across on demand durability and payer contracting strength if visit volumes and revenue per visit trends persist.
Density growth and new-geography entry strategy could influence competitive dynamics in the largest US metro markets where LifeStance operates.
Limited direct global impact; primarily a US healthcare services earnings/guidance signal.
Counterpoint
Margin expansion may be partly timing-driven (collections and payroll timing), and the 2027 EHR transition could temporarily pressure clinician productivity and utilization.
Key entities
- companyLifeStance Health
Reported Q2 2026 results and raised FY 2026 guidance, with detailed operating metrics and margin/cash flow commentary.
- executiveDavid Bourdon
CEO who discussed productivity blips tied to the planned 2027 EHR transition and clinical outcomes from patient analysis.
- executiveRyan McGroarty
CFO who commented on margin trajectory and cash flow impacts from payroll and 401(k) matching.
